**
In a landmark shift for women’s health, the long-misunderstood condition polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS). This change, announced at the European Congress of Endocrinology in Prague, marks the culmination of over a decade of collaboration among medical professionals and patient advocacy groups, aiming to better reflect the complexity of the disorder that affects approximately 170 million women globally.
Understanding the Renaming of PCOS
The change in nomenclature from PCOS to PMOS has been driven by the need to address the misconceptions surrounding the condition. Traditionally, the term ‘polycystic’ suggested a focus solely on the ovaries, leading to confusion and misdiagnosis. According to Professor Helena Teede, director of the Monash Centre for Health Research & Implementation in Melbourne, this outdated terminology failed to encompass the full spectrum of symptoms and health risks associated with the condition, which includes metabolic issues, insulin resistance, and an increased likelihood of diabetes and heart disease.
Teede articulated the necessity of this change, stating, “The term PCOS didn’t capture the multi-system burden that people with this condition have suffered.” The new designation aims to shift the focus from a narrow view of ovarian health to a broader understanding of the endocrine and metabolic implications that PMOS entails.
The Impact on Patients
Maddy Mavrikis, a young woman from Sydney, represents the many who have struggled with the implications of a PCOS diagnosis. Diagnosed at the age of 15, Mavrikis faced significant misinformation about her fertility and overall health. “I never had – and still don’t have – cysts on my ovaries, so I never really understood why I was diagnosed with ‘polycystic ovaries’,” she shared, highlighting the confusion that often accompanies the condition.
Mavrikis’ experience illustrates a common narrative among those diagnosed with PMOS. Many patients report an uphill battle in receiving accurate diagnoses and effective treatment. Notably, around 85% of women with PMOS also experience insulin resistance, a critical factor that has often been overlooked in traditional treatments.
A Collaborative Effort for Change
The push for renaming the condition was not merely a matter of semantics; it represented a significant cultural shift in how women’s health issues are perceived and addressed. The initiative involved extensive discussions with 56 medical and patient societies worldwide, ensuring that the voices of those living with PMOS were at the forefront of the decision-making process.
Lorna Berry, a long-time advocate for better education around PCOS, participated in workshops that led to the name change. She noted the importance of patient input, stating, “When I’ve been in the room with these people that are very smart and have all this medical knowledge, I’ve felt an equal.” This inclusive approach aimed to dismantle the stigma associated with reproductive health conditions, particularly in regions where a woman’s worth can be tied to her reproductive capabilities.
The Path Forward
As part of the transition, the new name PMOS will be fully integrated into international guidelines by 2028. This update is not just about changing a label; it is about instilling a deeper understanding of the condition that affects so many women. By moving away from the misleading term ‘polycystic’, medical professionals hope to foster more comprehensive care that addresses the full range of symptoms and potential health risks associated with PMOS.
Mavrikis expressed optimism about the name change, stating, “Changing the name, for me, shows that they are starting to pay attention to it.” This sentiment resonates with many who have felt sidelined in discussions about their health and underscores the importance of continual advocacy for women’s health issues.
Why it Matters
The renaming of PCOS to PMOS is a significant milestone in the ongoing battle for better recognition and understanding of women’s health conditions. By accurately reflecting the complexity of the syndrome, this change serves not only to enhance medical care but also to empower women to advocate for themselves and seek comprehensive treatment options. As awareness spreads, it is hoped that future generations will face fewer barriers in understanding and managing their health, leading to improved outcomes and a greater quality of life for those affected by PMOS.
